TrialBreast cancer (Tokyo, Japan)2025

Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.

Eriko Tokunaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.